Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema

• Authors: VALERIEVA Anna; STAEVSKA Maria; JESENAK Milos; HRUBISKOVA Katarina; SOBOTKOVA Marta; ZACHOVA Radana; HAKL Roman; ANDREJEVIC Sladjana; SUITER Tobias; GRIVCHEVA-PANOVSKA Vesna; KARADZA-LAPIC Ljerka; SOTERES Daniel; SHAPIRO Ralph; RUMBYRT Jeffrey; TACHDJIAN Raffi; MEHTA Vinay; HSU F. Ida; ZANICHELLI Andrea
• Year of publication: 2020
• Type: Article in Periodical
• Magazine / Source: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
• MU Faculty or unit: Faculty of Medicine
• Web: http://dx.doi.org/10.1016/j.jaip.2019.08.011
• Doi: http://dx.doi.org/10.1016/j.jaip.2019.08.011
• Keywords: C1-INHIBITOR; ATTACKS; DEFICIENCY; EFFICACY
• Description: Hereditary angioedema (HAE), an inherited deficiency offunctional C1 esterase inhibitor (C1-INH), is characterized byrecurrent episodes of disabling and often painful swelling insubcutaneous and/or submucosal tissues.1HAE attacks aregenerally unpredictable, but triggers for an attack can includehaving a dental or medical procedure (eg, surgery), other trauma,or stress. A preemptive management plan for patients under-going these types of situations may reduce the risk of HAE at-tacks. Recommendations include administration of short-termprophylaxis in patients with HAE before invasive medical pro-cedures, especially those involving the upper airways or digestivetract, with C1-INH concentrate typically the medication ofchoice.